

# CALL FOR PROPOSALS

## Swiss Cancer Institute / Astellas & AstraZeneca Translational GU Oncology Research Award

Application deadline: April 27, 2026


The Translational GU-Oncology Research Award supports ongoing **translational research** projects in the field of urogenital oncology. The funding is provided in equal parts by Astellas and AstraZeneca and is intended to promote innovative approaches in clinical and translational research.

The grant is endowed with CHF 10 000.–.

---

Featuring two keynote lectures by leading experts during the abstract presentations:

- Gert Attard, MD, PhD, UCL Cancer Institute, UK
- Karim Fizazi, MD, PhD, University of Paris Saclay and Centre Oscar Lambret, France



## APPLICANTS

- Doctoral students, postdoctoral researchers and clinically active scientists (physician-scientists) who are involved in translational or clinical research
- Have the primary place of work in Switzerland.
- Must finance the project via an institutional/healthcare organization bank account

## ELIGIBLE PROJECTS

- Projects should be translational in nature. They should be aimed at translating basic research discoveries into the clinic.
- Possible projects could include, but are not limited to:
  - Development of novel treatments for GU cancers focused on small molecules, biologics, or radioligand therapies
  - Development of diagnostic modalities for GU cancers
  - Development of novel prevention strategies for GU cancers
- Approaches can include preclinical, animal, human tissue, and/or human studies and must be conducted in Switzerland but can be part of larger collaborative projects. In the case of the latter, the submitted project should be a substantial part of such an overarching project and focus on a specific aspect.

## OUT OF SCOPE

Purely basic research projects

For the full requirements on the eligibility of the projects, please read the «Rules & Regulations» on the Swiss Cancer Institute website [www.swisscancerinstitute.ch](http://www.swisscancerinstitute.ch)

## SUBMISSION

Your application must be submitted electronically via [events@swisscancerinstitute.ch](mailto:events@swisscancerinstitute.ch)



Application deadline: April 27, 2026

After the submission deadline, the Scientific Committee will carefully review all submitted applications and invite 6 to 8 applicants to present their project at the **Translational Urogenital Network Meeting on June 18/19, 2026** in Baden AG. Accommodation will be provided for all invited applicants. Following all presentations, the Scientific Committee will select the winning project.

## MEETING PROGRAM

**18 June**, Start 18:00h with Keynote lecture by Karim Fizazi, MD, PhD, University of Paris Saclay and Centre Oscar Lambret, France, abstract presentations and networking dinner

**19 June**, Start 09:00h with Keynote lecture by Gert Attard, MD, PhD, UCL Cancer Institute, UK, abstract presentations and award ceremony. End ca. 12:00h

## FOR MORE INFORMATION

Swiss Cancer Institute

Tel: +41 31 389 91 91

E-Mail: [events@swisscancerinstitute.ch](mailto:events@swisscancerinstitute.ch)

Sponsors: Astellas Pharma AG · Richtiring 28 8304 Wallisellen · [www.astellas.com](http://www.astellas.com) | AstraZeneca AG · Neuhofstrasse 34 6340 Baar · [www.astrazeneca.ch](http://www.astrazeneca.ch)